Skip to navigation Skip to content

T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112

Expand/Collapse all sectionsExpand all


T-cell Lymphoma restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngT-cell lymphoma (CTCL or PTCL) restriction and item codes

Contact details

Complex Drugs Programs team

Forms

Cutaneous T-cell lymphoma (CTCL) – vorinostat - initial authority application (PB216)

Cutaneous T-cell lymphoma (CTCL) – brentuximab vedotin - initial authority application (PB268)

Peripheral T-cell lymphoma (PTCL) – brentuximab vedotin - initial authority application (PB314)

Services Australia website

T-cell lymphoma

External websites

PBS schedule for T-cell lymphoma

Frequently asked questions

Item

Description

1

Where do I process Initial and Continuing CTCL/PTCL applications?

You will enter Initial and Continuing CTCL/PTCL applications into the Online PBS Authorities system. Checking patient history is not required.

2

Do I need to check if the patient has had an initial before processing a continuing application?

There are parameters built into the system that will check that an initial has been provided before a continuing is approved. If there is a rejection message suggesting no initial has not been approved but the prescriber indicates the patient has had the initial authority approval, search the patient’s history on mainframe/OPA for confirmation and escalate to a PA if you suspect there is incorrect rejection.